{"id":542611,"date":"2021-05-10T23:08:01","date_gmt":"2021-05-10T23:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542611"},"modified":"2021-05-10T23:08:01","modified_gmt":"2021-05-10T23:08:01","slug":"angioimmunoblastic-tcell-lymphoma-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/angioimmunoblastic-tcell-lymphoma-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_542611.html","title":{"rendered":"Angioimmunoblastic T-cell Lymphoma Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By Delveinsight"},"content":{"rendered":"
\"Angioimmunoblastic<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Angioimmunoblastic T-Cell Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Angioimmunoblastic T-Cell Lymphoma, historical and forecasted epidemiology as well as the Angioimmunoblastic T-Cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Angioimmunoblastic T-cell Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a><\/p>\n

DelveInsight’s “Angioimmunoblastic T-cell Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″ report delivers an in-depth understanding of the  Angioimmunoblastic T-cell Lymphoma, historical and forecasted epidemiology as well as the  Angioimmunoblastic T-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    A study stated that AITL were reported to be more common in Europe (28.7%) compared to North America (16%) and Asia (17.9%). With respect to rarer extranodal forms (excluding primary cutaneous ALCL), most of the cases were diagnosed in Europe (2.8%) and only a few cases were reported in North America and Asia (1.6% and 1.5%, respectively). AITL is confirmed as a distinctive disorder in Europe, while in South America, NKCL and ALK-negative ALCL represent the most common subtypes.<\/p>\n<\/li>\n

  2. \n

    A study, which stated that AITL comprises 1-2% of non-Hodgkin lymphoma (NHL), 15-20% of peripheral T-cell lymphoma (PTCL). Geographically, more prevalent in Europe (28.7% of all PTCL) followed by Asia (17.9%) and North America (16.0%). As per the estimates, 0.05 new cases diagnosed per 100,000 patients in the United States per year.<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1.  Angioimmunoblastic T-cell Lymphoma market report covers a descriptive overview and comprehensive insight of the  Angioimmunoblastic T-cell Lymphoma epidemiology and  Angioimmunoblastic T-cell Lymphoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2.  Angioimmunoblastic T-cell Lymphoma market report provides insights on the current and emerging therapies.<\/p>\n

    3.  Angioimmunoblastic T-cell Lymphoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/p>\n

    4. The  Angioimmunoblastic T-cell Lymphoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the  Angioimmunoblastic T-cell Lymphoma market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/angioimmunoblastic-t-cell-lymphoma-atcl-market<\/span><\/a><\/strong><\/strong><\/p>\n

    Angioimmunoblastic T-cell Lymphoma: Overview<\/strong><\/p>\n

    Angioimmunoblastic T-cell lymphoma (AITL) is a rare form of non-Hodgkin lymphoma, which is a group of related malignancies (cancers) that affect the lymphatic system (lymphomas). Lymphomas are cancer of white blood cells (lymphocytes) and can be divided depending on the type of cells, B-lymphocytes (B-cells) or T-lymphocytes (T-cells), AITL is a T-cell lymphoma.<\/p>\n

    The key player involved in the Angioimmunoblastic T-cell Lymphoma market:<\/strong><\/a><\/p>\n

      \n
    1. \n

       Celgene, <\/p>\n<\/li>\n

    2. \n

      Verastem, <\/p>\n<\/li>\n

    3. \n

      Beigene, <\/p>\n<\/li>\n

    4. \n

      Merck Sharp & Dohme Corp.<\/p>\n<\/li>\n

    5. \n

      Solasia Pharma, <\/p>\n<\/li>\n

    6. \n

      Kura Oncology  <\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Angioimmunoblastic T-cell Lymphoma treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drugs covered<\/strong><\/p>\n

        \n
      1. \n

        Azacitidine (CC-486)<\/p>\n<\/li>\n

      2. \n

        Copiktra (Duvelisib<\/p>\n<\/li>\n

      3. \n

        Tislelizumab (BGB-A317)<\/p>\n<\/li>\n

      4. \n

        Keytruda<\/p>\n<\/li>\n

      5. \n

        SP-02 (darinaparsin)<\/p>\n<\/li>\n

      6. \n

        Tipifarnib<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/angioimmunoblastic-t-cell-lymphoma-atcl-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4.  Angioimmunoblastic T-cell Lymphoma Patient Share (%) Overview at a Glance<\/p>\n

        5.  Angioimmunoblastic T-cell Lymphoma Market Overview at a Glance<\/p>\n

        6.  Angioimmunoblastic T-cell Lymphoma Disease Background and Overview<\/p>\n

        7.  Angioimmunoblastic T-cell Lymphoma Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of  Angioimmunoblastic T-cell Lymphoma<\/p>\n

        9.  Angioimmunoblastic T-cell Lymphoma Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11.  Angioimmunoblastic T-cell Lymphoma Emerging Therapies<\/p>\n

        12.  Angioimmunoblastic T-cell Lymphoma Market Outlook<\/p>\n

        13. Country-Wise  Angioimmunoblastic T-cell Lymphoma Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18.  Angioimmunoblastic T-cell Lymphoma Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Angioimmunoblastic T-cell Lymphoma- Pipeline Insights, 2021<\/strong><\/p>\n

        “Angioimmunoblastic T-cell Lymphoma Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the  Angioimmunoblastic T-cell Lymphoma market. A detailed picture of the  Angioimmunoblastic T-cell Lymphoma pipeline landscape is provided, which includes the disease overview and  Angioimmunoblastic T-cell Lymphoma treatment guidelines.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight’s “Angioimmunoblastic T-Cell Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Angioimmunoblastic T-Cell Lymphoma, historical and forecasted epidemiology as well as the Angioimmunoblastic T-Cell Lymphoma market trends in the … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-542611","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542611"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542611\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}